Markets

Agile Therapeutics, Inc. (AGRX): Checking the Operational Data

Agile Therapeutics, Inc. (NASDAQ:AGRX) is in the highlights and many would want to know whether now might be a good time for it to present much upside. Now trading with a market value of 20.69M, the company has a mix of catalysts and obstacles that spring from the nature of its operations. Everyone seems to have their own opinion of this stock. But what do the numbers really say? We think it’s a great time to take a fresh look.

Agile Therapeutics, Inc. (NASDAQ:AGRX) Fundamentals That Matter

It’s generally a good idea to start with the most fundamental piece of the picture: the balance sheet. The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For AGRX, the company currently has 28.34 million of cash on the books, which is offset by 9.09 million in current liabilities. The trend over time is important to note. In this case, the company’s debt has been growing. The company also has 42.92 million in total assets, balanced by 12.31 million in total liabilities, which should give you a sense of the viability of the company under any number of imagined business contexts.

Agile Therapeutics, Inc. (AGRX) saw -5.99 million in free cash flow last quarter, representing a quarterly net change in cash of -7.61 million. Perhaps most importantly where cash movements are concerned, the company saw about -5.72 million in net operating cash flow.

But what about the bottom line? After all, that’s what really matters in the end. Agile Therapeutics, Inc. (AGRX) is intriguing when broken down to its core data. The cost of selling goods last quarter was 6,000, yielding a gross basic income of -6,000 . For shareholders, given the total diluted outstanding shares of 34.23 million, this means overall earnings per share of -0.20. Note, this compares with a consensus analyst forecast of -0.16 in earnings per share for its next fiscal quarterly report.

Is Agile Therapeutics, Inc. (NASDAQ:AGRX) Valuation Attractive



Looking ahead at valuations, according to the consensus, the next fiscal year is forecast to bring about -0.72 in total earnings per share. If we consider a median price to earnings ratio on the stock, that corresponds with a stock price of 9,999. However, one should always remember: the trends are more important than the forecasts. This continues to be an interesting story, and we look forward to updating it again soon on Agile Therapeutics, Inc..

Previous ArticleNext Article

Related Post

What Recent Ownership Trends Suggest About Micron ... Recent insider trends for Micron Technology, Inc. (NASDAQ:MU) have caught the attention of investors. Analysts monitor insider data to understand the ...
UnitedHealth Group Incorporated (UNH) Forming A Pa... UnitedHealth Group Incorporated (NYSE:UNH) is one of the more popular stocks investors are adding into their watchlist. Now trading with a market valu...
Berkshire Hathaway Inc. (BRK-B): Does This Move Ma... Berkshire Hathaway Inc. (NYSE:BRK-B) is in the highlights and many would want to know whether now might be a good time for it to present much upside. ...
Spirit Airlines, Inc. (SAVE): Checking the Operati... Spirit Airlines, Inc. (NYSE:SAVE) trade is getting exciting but lets take a deeper look whether it is as good a moment. Now trading with a market valu...
Looking at the Big Picture for Energy Transfer Equ... Energy Transfer Equity, L.P. (NYSE:ETE) seems to be forming a pattern of major movements, providing only some crumbs of outlook for market participant...